Introduction

Immersive neurotechnology refers to technologies that directly or indirectly interact with the human nervous system to influence, record, interpret, or augment neural activity. Examples may include brain-computer interfaces, neural implants, neurofeedback systems, immersive virtual-reality environments, cognitive enhancement devices, and systems capable of translating neural signals into digital commands. As these technologies become more sophisticated, ordinary medical-device, data-protection, consumer-protection, and professional-liability rules may become insufficient to address their risks.

An immersive neurotechnology accountability doctrine would establish legal responsibility for developers, manufacturers, healthcare professionals, operators, institutions, and users when neurotechnological systems cause physical, psychological, cognitive, informational, or economic harm. The doctrine should be based upon autonomy, informed consent, mental privacy, safety, transparency, cybersecurity, proportionality, and effective remedies.

Constitutional foundations

In India, the constitutional basis for regulating immersive neurotechnology can principally be derived from Articles 14, 19 and 21. Article 21 protects life and personal liberty, while privacy and dignity provide important safeguards against intrusive technologies.

In Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), the Supreme Court recognised privacy as a fundamental right and connected it with dignity, autonomy and control over personal information. The judgment is highly relevant by analogy because neural information can reveal exceptionally intimate information concerning cognition, preferences, emotional states and potentially mental processes.

The proportionality principles developed through the privacy jurisprudence would require intrusive neurotechnology to have a legitimate purpose, a rational connection to that purpose, necessity and appropriate safeguards against excessive interference.

Mental privacy and cognitive liberty

Immersive neurotechnology creates a distinctive category of risk because interference may occur inside the user's cognitive environment rather than merely through conventional physical intrusion.

In Selvi v. State of Karnataka (2010), the Supreme Court considered involuntary techniques involving narco-analysis, polygraph examination and brain-related investigation. The Court emphasised personal liberty, mental privacy and the importance of consent. Although immersive neurotechnology was not before the Court, the reasoning provides a strong foundation for regulating technologies capable of accessing or influencing neural activity.

A future accountability doctrine should therefore recognise cognitive liberty as a protected interest. Users should generally retain the right to decide whether their neural activity is collected, interpreted, stored, shared or used to influence decisions.

Informed consent and medical accountability

Where immersive neurotechnology is used for diagnosis, treatment, rehabilitation or enhancement, informed consent should be a central requirement.

In Samira Kohli v. Dr. Prabha Manchanda (2008), the Supreme Court stressed the importance of informed consent before medical intervention. Applied by analogy, consent for neurotechnology should explain not merely ordinary medical risks but also potential effects on cognition, behaviour, emotional states, privacy and future data use.

Healthcare providers may also incur professional liability where unreasonable negligence causes harm. Jacob Mathew v. State of Punjab (2005) established important principles concerning medical negligence. Neurotechnology providers should consequently be required to maintain appropriate professional standards, technical competence and monitoring systems.

Manufacturer and developer responsibility

Manufacturers and developers should bear responsibility for foreseeable risks arising from defective design, inadequate testing, misleading claims, insufficient warnings or negligent software updates.

A regulatory system should distinguish between unavoidable technological risks and preventable design failures. High-risk neurotechnology should undergo rigorous pre-market testing and continuing post-market surveillance.

Particular attention should be given to:

neural-signal accuracy;

unintended cognitive or behavioural effects;

device malfunction;

algorithmic errors;

cybersecurity vulnerabilities;

unauthorized neural-data extraction;

harmful immersive environments;

software-update risks; and

interoperability with other digital systems.

Where manufacturers use artificial intelligence to interpret neural signals, explainability and auditability should also become part of accountability requirements.

Neural-data governance

Neural information should receive enhanced protection because it can potentially reveal characteristics far more intimate than ordinary consumer information. A governance framework should therefore impose strict limits on collection, retention, secondary use and commercialisation.

Consent should be specific and meaningful rather than hidden within lengthy general terms of service. Users should also have mechanisms to withdraw consent where technically and legally feasible.

The privacy principles established in Puttaswamy support treating control over highly sensitive personal information as an important element of individual autonomy. Any governmental or commercial collection of neural information should therefore satisfy legality, necessity and proportionality requirements.

Cybersecurity and algorithmic accountability

Immersive neurotechnology may create a new class of cybersecurity risks. A compromised neural interface could potentially interfere with physical devices, manipulate feedback or expose sensitive cognitive information.

Accordingly, manufacturers and operators should implement security-by-design obligations. These should include encryption, authentication, access controls, vulnerability testing, incident reporting and secure software updates.

Algorithmic decisions affecting medical treatment, employment, insurance, education or access to services should also be subject to human oversight. A person should have an opportunity to challenge consequential decisions based upon potentially inaccurate neural interpretations.

Consumer and commercial accountability

Commercial neurotechnology raises concerns about deceptive advertising and exploitation. Companies should not make unsupported claims that their products can improve intelligence, memory, emotional control or neurological performance.

Consumer-protection rules should require evidence-based advertising and transparent disclosure of material limitations. Contract terms attempting to exclude responsibility for foreseeable neurological harm should receive strict scrutiny, particularly where consumers lack meaningful bargaining power.

Institutional governance

Hospitals, schools, workplaces, research institutions and other organisations using immersive neurotechnology should establish internal governance systems.

A comprehensive framework should include:

ethics and safety review before deployment;

documented informed consent;

designated accountability officers;

continuous monitoring for adverse effects;

strict neural-data access controls;

independent complaint mechanisms;

mandatory incident reporting;

periodic technology audits; and

accessible compensation mechanisms.

Employment settings require particular safeguards because consent may not be genuinely voluntary where refusing neurotechnology could affect employment opportunities.

International legal principles

The European human-rights framework provides useful comparative principles. S. and Marper v. United Kingdom (2008) recognised important privacy concerns associated with retention of sensitive biological information. Although the case involved DNA rather than neural data, it illustrates how highly personal biological information can engage Article 8 of the European Convention on Human Rights.

Similarly, Pretty v. United Kingdom (2002) connected private life with personal autonomy. The reasoning can be relevant by analogy to technologies affecting bodily and cognitive self-determination.

These principles suggest that future neurotechnology regulation should protect not only physical integrity but also psychological and informational autonomy.

Proposed accountability doctrine

A mature immersive-neurotechnology accountability doctrine should apply a risk-based responsibility model. The greater the technology's capacity to influence or access neural processes, the greater the developer's and operator's legal duties should be.

Responsibility should be distributed according to control over the relevant risk. Developers should be responsible for design and engineering failures; healthcare professionals for clinical decisions and informed consent; institutions for governance and supervision; operators for misuse; and users for intentional unlawful conduct.

No organisation should be permitted to avoid responsibility merely by describing a neurotechnology product as experimental, artificial-intelligence-based, or consumer-oriented.

Conclusion

Immersive neurotechnology challenges conventional legal accountability because it can affect the body, mind and information simultaneously. Indian constitutional principles, particularly privacy, dignity, autonomy and personal liberty, provide a strong foundation for developing appropriate safeguards.

Puttaswamy, Selvi, Samira Kohli, and Jacob Mathew provide important principles by analogy concerning privacy, mental autonomy, informed consent and professional responsibility. Future governance should combine these principles with medical-device regulation, data protection, cybersecurity, consumer protection and institutional oversight.

The central rule should be that technological access to the human nervous system does not reduce the individual's legal protection. Instead, greater technological capacity to observe or influence cognition should correspond to greater duties of care, transparency, consent and accountability.